Krueppel-like factor 15 Antibodies

Krueppel-like factor 15 (KLF15)

Transcriptional regulator that binds to the GA element of the CLCNKA promoter. Binds to the KCNIP2 promoter and regulates KCNIP2 circadian expression in the center (By similarity).

Is a repressor of CTGF expression, involved in the management of cardiac fibrosis. It is also involved in the management of cardiac hypertrophy acting through the inhibition of MEF2A and GATA4 (By similarity).

Gene Information

Human
Gene Name:	KLF15
Uniprot:	Q9UIH9
Entrez:	28999

Family

Belongs to:
Sp1 C2H2-type zinc-finger protein family

Alternative Names

DKFZp779M1320; kidney-enriched Kruppel-like factor; KKLFKidney-enriched krueppel-like factor; Krueppel-like factor 15; Kruppel-like factor 15

Molecular Weight

Mass (kDA):
43.992 kDA

Genomic Context

Human
Location:	3q21.3
Sequence:	3; NC_000003.12 (126288121..126357408, complement)

Tissue Specificity

Highly expressed in liver, skeletal muscle, and kidney. Expressed in cardiomyocytes. Expression is highly reduced in cardiac tissue of patients with non-ischemic cardiomyopathy and aortic aneurysm, and in glomerular disease. Not expressed in bone marrow or lymphoid tissues.

Subcellular Localizations

Nucleus.

Diseases

• Hypertrophy
• Obesity
• Heart Failure
• Insulin Resistance
• Diabetes Mellitus
• Cardiac Hypertrophy
• Fibrosis
• Inflammation
• Kidney Diseases
• Facial Paralysis
• Malignant Neoplasms
• Chronic Kidney Disease

• Mammary Neoplasms
• Diabetes Mellitus, Non-insulin-dependent
• Glomerulosclerosis (disorder)
• Stenosis
• Left Ventricular Hypertrophy
• Hyperglycemia
• Proteinuria Of Undiagnosed Cause

Interacting Proteins

• PRKAB2
• ZBTB24

Pathways

• Transport
• Localization
• Gluconeogenesis
• Glucose Transport
• Glucose Homeostasis
• Cell Cycle
• Cell Differentiation
• Cell Proliferation
• Energy Homeostasis
• Dna Replication
• Regulation Of Gluconeogenesis
• Cell Growth
• Pathogenesis

• Hyperphosphorylation
• Brain Development
• Aging
• Neurogenesis
• Regulation Of Gene Expression
• Oxidative Phosphorylation
• Chondrocyte Hypertrophy

PTMs

• Phosphorylation
• Acetylation

• Oxidation
• Deacetylation

• Methylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/KLF15

Best Uses Of The KLF15 Marker

RNA isolation and cDNA synthesis are essential for the identification of genes that express KLF15. High-affinity primary antibodies are also useful in analyzing cDNA synthesis. This article gives an overview on the high-affinity KLF15 antigen. Continue reading to find out more. Here are some other tips:

Isolation RNA

The Boster Bio KLF15 marker for mRNA isolation is a highly specific peptide marker for the gene KLF15. It has been shown that KLF15 is a key regulator for cardiomyocyte hypertrophy. Knockdown of KLF15 increased leucine incorporation and augmented the hypertrophic effect of AngII. KLF15 knockdown was also shown to increase leucine incorporation within cardiomyocytes when used with b-LGND and E2. This confirms siRNA inhibition of KLF15.

In a short term experiment, 100 uL of whole-blood was used to extract total RNA using the RNAiso Bloodkit. To determine the integrity of the RNA, the RNA was mixed with 30 uL Milli-Q Water after it had been pelleted. The RNA integrity of eight samples was 8.8, indicating that the RNAs can be used to prepare libraries for total RNA sequence.

cDNA synthesis

Total RNA from rat kidney tissues was extracted and used as a template to cDNA synthesis using TRIzol, Invitrogen. The kit contained a single-stranded RNA or DNA primer, and it synthesized complementary strands using the SuperScript cDNA system. Biotinylated UTP (and CTP) were used for in vitro transcriptomy. After cDNA synthesis was completed, the target cRNAs had to be fragmented and cleaned.

The promoter regions for the KLF15 gene have seven-five kilobase (bp), which range from 7500 to +2000bp. PCR primers were created to detect mutations at GRE1 or GRE2. The KLF15 gene can be expressed in bovine Adipocytes. Ectopic expression of this gene causes rhodopsin to stop working. The KLF15 Gene is also crucial for lung adenocarcinoma (lung adenocarcinoma) cell proliferation. The gene is also involved with the regulation of CDKN1A/p21 as well as CDKN1C/p57 which inhibit GC cell proliferation.

KLF15 in mice is overexpressed and podocyte differentiation accelerates. Differentiating podocyte markers are also expressed significantly. KLF15 overexpression significantly increases podocyte differentiation, and protects the kidney against injury. Podocytes deficient in KLF15 show no signs of glomerulosclerosis. This finding suggests that KLF15 may be an essential regulator of podocyte differentiation.

KLF15 is highly expressed within the kidneys, but its levels are decreased in glomerular disorders. The KLF15 marker can be used to synthesis cDNA, which may help us understand the mechanism leading to podocyte injury. Further studies are needed in order to determine the protective function of KLF15 for human glomerular diseases. This gene is a good candidate for a human model of kidney disease.

KLF15 is overexpressed in HIV-1-infected cell lines and induces podocyte differentiation. KLF15 can also bind to the promoter region of genes that encode podocyte differentiation markers. To test this hypothesis, murine Podocytes were transfected with KLF15 (or a control vector) and tested for proteinuria as well as reduced expression of podocyte differentiation marker genes. KLF15 expression in HIVAN models is decreased in podocytes as well as in human kidney biopsy specimens.

High-affinity primary antibodies

BosterBio's laboratory produces high affinity primary antibodies. They can be used in many applications, such as immunohistology, ELISA and Western blot. The antibodies have been rigorously tested and have received over 29,000 citations in scientific publications. They are also optimized for use with WB and ELISA.

Steven Boster was the first to develop high-affinity primary antibodies. After developing different products for IHC and immunohistochemistry, Boster grew to become one of the largest antibody catalogs in China. PicoKine(tm), Boster's proprietary ELISA platform was launched in the late nineties. PicoKine(tm), a proprietary technology, is based on trade secrets which have allowed the company to develop the best products for research. This proprietary platform has helped Boster develop some of the highest-sensitivity ELISA kits available on the market.

Boster Bio Anti–KLF15 antibody comes in 100ul. It has been tested in IP and WB. Boster Bio Anti KLF15 antibody has been tested in IP, IHC, and reacts with Human. The antibodies are supplied in a Liquid form. The results of these experiments were then examined using a Nikon Eclipse E600 Epi fluorescence microscope.

The KLF15 antibody has been used to label cardiomyocytes. The cells were cultured on collagen coated glass cover slips and were then treated with various substances. After transfection, cells were washed three time with PBS, and then fixed for 10 minutes with 4% paraformaldehyde. After 48 hours, fresh media was added to the cells. The cells were then washed 3 times with PBS. FACS or immunoblots can be done after 48 hours. Afterward, the samples were stained with secondary antibodies conjugated with the KLF15 marker.

The high-affinity primary antibodies can also be conjugated with different markers. These primary antibodies are useful in immunohistochemistry experiments to measure the presence of certain types or cells. These antibodies are also useful in flow cytometry which measures the number certain types of cell types. These secondary antibodies can be conjugated to various substrates, including phospholipids and oligosaccharide.

The KLF15 mRNA protein and AngII b-LGND were measured using AngII, b–LGND, and a p38 analog. SB2036580 is an AngII inhibitor that inhibits p38a activity, which is responsible to inhibit the KLF15 mRNA and protein. TGFb, AngII and b-LGND were used to further test the antibodies.